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Abstract 
We review the key building blocks of a design framework for modeling and 
optimizing biomedical systems under development in the Biological Systems 
Engineering Laboratory and the Centre for Process Systems Engineering at 
Imperial College. The framework features the following components: (i) in vitro 
environment, where model parameters can be obtained and new setups can be 
tested; (ii) in silico environment, including a simulation module for representing 
relevant physical or biological processes, and an optimization module, for 
calculating of improved in vitro or in vivo outcomes; (iii) in vivo environment, 
from which organ and patient-specific parameters are collected and which can 
also implement personalized suggestions for improved outcomes. Two 
applications in the area of healthy and diseased blood are thoroughly discussed 
to exemplify the framework's characteristics. We discuss progress in the 
different areas and the way in which they are connected and finally propose a 
hybrid in vitro/in silico/in vivo platform. 
 
Keywords: Biomedical design framework; Red blood cell production; 
Bioreactor design; Chemotherapy modeling and optimization for leukemia; Cell 
cycle; Environmental stress 
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1. Introduction  
One of the most prominent features of modeling biomedical systems is the 
existence of phenomena occurring at multiple scales. Between molecular, 
cellular, patient and population scales, appropriate translations are necessary for 
evaluating the effects small-scale processes have at large scale and vice-versa 
(Hall et al, 2011). Deriving patient data directly is not always possible, thus 
making ex vivo observations and studies imperative. For the latter to be 
accomplished it is essential to develop appropriate experimental setups that 
reproduce in vitro the biological characteristics and behavior of the in vivo 
system. In silico techniques may bridge the gap between the in vitro and in vivo 
scales, through simulating the patient response (Androulakis, 2014; Chen et al., 
2012; Harrold and Parker, 2009; Ho et al, 2013). The study of normal and 
abnormal blood production faces these challenges and many others related to 
the complexity of the underlying biological system and the heterogeneity 
observed in hematological malignancies. 
 
The current trends and developments in genomics, proteomics and 
metabolomics open the possibility for obtaining specific information related to 
the genetic characteristics, together with the proteomic and metabolomics 
profiles of an individual patient, which can then be used towards personalized 
medicine (Saha et al., 2014). In this context, personalized healthcare is expected 
to deliver a step change in quality and value of care, through more precise and 
personalized diagnostics as well as cost-effective and targeted therapies. Some 
of the challenges in the delivery of personalized medicine lie in (a) In vitro: the 
fidelity and validity of current experimental systems used to investigate human 
diseases; (b) In silico: the integration of patient-specific and disease-specific 
datasets and the development of validated predictive adaptive models; and (c) 
In vivo: the application of these models to identify simple targets and more 
efficient, yet less toxic therapies and drugs for a specific condition.  
 
Here, we present the fundamental features of an integrated framework which 
aims to address (some of) these challenges - with main focus on healthy and 
diseased blood. An earlier version of this manuscript appeared as a conference 
manuscript (Velliou et al., 2014e); this full length manuscript clarifies and 
extends the previous work. 
2. Design framework. 
Figure 1 presents key building blocks of the integrated design framework under 
development at the Biological Systems Engineering Laboratory (BSEL) and the 
Centre for Process Systems Engineering (CPSE) at Imperial College. As a 
whole, the framework aims at closing the loop by collecting relevant data in 
vivo and/or in vitro in order to predict and/or improve real outcomes through in 
silico calculations. 
From the scale point of view (represented as rows on Figure 1), biomedical 
systems' circuitry can be defined as the abstract representation of physiological 
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processes into a network of compartments where exchange and/or reaction can 
take place at different levels. These physiological processes are subject to 
external cues that are tunable depending on medical/biological needs. Thus, the 
backbone of the design framework is composed of the following elements, 
under all three environments (in vitro, in vivo, in silico): (i) chemical 
stimulation: administering molecules capable of interacting with cellular 
material for inducing the desired transformation; (ii) molecular transport, either 
with biological modification (activation, degradation, elimination) or 
unmodified, to the target point of action; (iii) effect: molecular interaction with 
the target cells to transform their characteristics towards the desirable outcome; 
(iv) cell growth: stem cell proliferation, defining overall cell number which 
could then become susceptible to transformation; and (v) cell metabolism: 
cellular interaction with its environment to exchange the resources needed to 
sustain cell growth. Note that not all systems need accurate representations at all 
scales. 
From the environment point of view (represented as columns on Figure 1), 
biomedical systems' processes are captured in vivo, in vitro and in silico. A 
particular system can incorporate two or more of the three environments: we 
will refer to in vitro / in silico systems as type 1, corresponding to laboratory 
setups, and to in vivo / in silico systems as type 2, tackling clinical treatment at 
the patient level.  
 
Type 1 systems feature an existing in vitro component which delivers a valuable 
product (cells, proteins, etc...) whose quality / quantity / cost is not satisfactory 
enough. Experimental data can be readily obtained (in accordance to GSA 
findings) and used to determine model parameters. The in silico component 
features mathematical representations of the relevant biological and physical 
processes occurring in vitro, simulating the experimental setup based on the 
aforementioned parameters. In silico optimization then computes an optimal 
scenario in which values of the operating variables are found that minimize cost 
/ maximize production / achieve a certain quality (all according to in vivo 
specifications), while satisfying the required constraints.  
 
Type 2 systems are composed of an in vivo component, corresponding to a 
particular patient undergoing medical treatment. Patient characteristics (in vivo 
specifications) and details of the treatment clinically administered are used to 
derive patient-specific parameters. Body processes affecting or affected by the 
medical treatment in vivo are rendered in silico through appropriate 
mathematical equations simulating patient response. Sensitivity analysis on the 
model points out which model parameters are most significant. If those 
parameters are not available from in vivo measurements, experiments have to be 
designed in order to specifically obtain the required parameters in vitro. Finally, 
in silico optimization calculates the optimal scenario on a case-by-case basis, by 
delivering values of the operating variables for maximizing treatment efficiency 
/ minimizing side-effects / minimizing treatment cost, in accordance with 
medical constraints. 
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This manuscript applies our systematic framework to two healthcare domains 
that exemplify type 1 and type 2 systems respectively (Sections 3 and 4): 
artificial blood production and personalized leukemia treatments. A brief 
overview of how the framework is applied to the treatment of diabetes and the 
control of anesthesia is given in Section 5.  
3. Artificial blood production: an example of a type 1 system 
Over fifteen million whole blood units are collected in the USA yearly 
(National Blood Collection and Utilization Survey, 2011); 1.9 million blood 
units were collected in the UK between 2012-2013 (NHS Blood and 
Transplant). But despite the success of coordinated blood collection and 
utilization: 3.3% of hospitals delay surgery because of blood shortages and 
10.3% of hospitals experience at least one day yearly when blood needs cannot 
be met (Timmins and Nielsen, 2009; Whitaker and Henry, 2011). Beyond 
shortages of commonly-stocked blood types, patients undergoing regular 
transfusions may require expensive rare blood donation to mitigate the risk of 
an immune response to foreign antigens (Tahhan et al., 1994; Meny et al., 
2013).  Ex vivo blood production is an attractive solution for filling shortage 
gaps and scaling-up rare blood donations. Current blood expansion protocols 
however require $8330 per unit of blood when an average hospital in the USA 
pays only $225.42 for a typical unit of blood and $1150 to $3025 for a unit of 
rare blood (Timmins and Nielsen, 2009; Whitaker and Henry, 2011; Meny et 
al., 2013).  Clearly, a more cost-effective solution needs to be implemented in 
order to shift towards artificial blood supply (Rodrigues et al., 2011). 
 
We propose a platform for on-demand artificial blood production, wherein 
umbilical cord HSCs are cultured in a biomimetic, cost-effective, 3D bioreactor, 
expanded and differentiated into red blood cells by careful signaling to 
externally control the same process of blood production that is diseased in 
leukemia (green panels, Figure 1).  
3.1. In vitro: A novel 3D bioreactor for ex-vivo culture of healthy and diseased 
blood 
Blood cell production takes place in the bone marrow (BM), a highly porous 
three dimensional organ of great complexity, where hematopoietic stem cells 
(HSCs) reside. HSCs in the BM receive appropriate signals to proliferate and 
specialize towards functional cellular units of the immune and oxygen-carrying 
systems (Quesenberry et al., 2001). These signals consist of both chemical 
(nutrients, oxygen and growth factors, which are signaling proteins that provide 
extracellular stimuli to the cells) and mechanical (adhesion, cell-cell contact) 
stimuli unique to the 3D microenvironment (Panoskaltsis et al., 2005). 
However, most current research is still performed in 2D culture systems, 
wherein the mechanical stimuli received by the cells are nonnative and thus the 
cellular proliferation is reduced. This limitation is typically overcome by 
increasing chemical stimulation from the expensive, specialized growth factor 
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proteins (Timmins and Nielsen, 2009). Taking into consideration the BM 
microenvironment architecture, we describe, in the sequel, development of two 
3D in vitro platforms which serve as an in vitro bone marrow mimicry allowing 
the expansion of normal and diseased blood. 
 
A 3D micro-bioreactor was developed by Mortera et al. (2010, 2011), consisting 
of highly porous Polyurethane (PU, pore size approximately 100μm), of 
dimensions 5x5x5 mm, as shown in Figure 2, which allows perfusion of 
nutrients and oxygen within the matrix. This micro-bioreactor successfully 
supported expansion and differentiation of Umbilical Cord Blood cells (blood 
cells with high proliferation/differentiation potential) without any exogenous 
cytokines for a time frame of 4 weeks, in contrast to traditional 2D culture 
systems that allowed Umbilical Cord Blood cells expansion only for a few days 
in absence of exogenous growth factors. However, in order to produce blood at 
quantities sufficient for transfusion purposes, it is essential to scale up the ex 
vivo blood expansion (Rousseau et al., 2014).  
 
Moving on that direction, we developed a 3D perfusion bioreactor (HFBR) 
capable of producing artificial blood (see Figure 3a; patented by Panoskaltsis et 
al., 2012). The HFBR enables red blood cell expansion at higher and continuous 
rate, by incorporating circulation of oxygenated nutritious medium, growth 
(stem cell factor - SCF) and differentiation (erythropoietin - EPO) factors. From 
an architectural point of view, the bioreactor is composed of a 3D polyurethane 
scaffold traversed by two different circuits as shown in Figure 3a, (i) a high-
uptake nutrient delivery circuit delivers nutrients and oxygen and removes 
waste through a plastic hollow fiber with very narrow pore size, (ii) a low-
uptake protein delivery circuit circulates EPO and SCF through a ceramic 
hollow fiber with larger pore size, allowing the exit of mature red blood cells 
(RBC) only. It recapitulates the architectural and functional properties of blood 
formation and thereby reduces the need for expensive growth factors by more 
than an order of magnitude. The RBCs produced comply with the in vivo 
specifications in terms of oxygen-carrying capacity, surface markers, and shape 
(Macedo, 2011).  
 
In comparison to other solutions for HSCs expansion, our HFBR achieves: 
(1) 10x lower cost (for the same cell production) with 28x lower bioreactor 
volume (for 1 unit of RBCs) (vs. perfusion bioreactor, Engelhardt et al, 
2011) 
(2) 18x higher cell production starting from the same cell density (vs. 
hollow fiber bioreactor, Chaudhuri and Al-Rubeai, 2005) 
(3) 5x lower cost (for the same cell production) with 4000x smaller 
volumes (vs. 2D, Neildez-Nguyen et al., 2002) 
 
A systematic framework for the design, simulation and optimization of of personalized healthcare: 
making and healing blood 7 
Experiments in the bioreactor are typically cost- and labor- intensive. Applying 
in silico optimization strategies for the design and operation of the bioreactor 
can be highly beneficial, as reviewed in the next section. 
 
3.2. In silico: Bioreactor design optimization 
Modeling in the bioreactor presented in Section 3.1 occurs across different 
scales: cellular growth, metabolism, fluid dynamics and chemical diffusion. 
Specifically, chemical stimulation is achieved by supplying SCF and EPO. 
Transport in the HFBR happens in two directions: perfusion of nutrients, 
oxygen and proteins in the bioreactor is modeled as axial flow within the fibers 
(3e), while diffusion in the scaffold occurs radially (3d). Mass exchange with 
cells within the scaffold results in the specific effects of the specialized 
proteins: growth (SCF) and differentiation (EPO). In the model, glucose 
corresponds to cellular nutrients for cell growth; lactate represents waste; 
oxygen stands in for cellular metabolism. The mathematical model for cellular 
growth, proliferation, and differentiation is derived from Ma et al. (2012) and 
Colijn et al. (2005). The model is implemented in GAMS 24.1 and solved using 
the MINLP solver ANTIGONE 1.1 (Misener and Floudas, 2013; 2014). 
 
Optimization aims at minimizing the cost of producing one unit of RBC while 
providing enough nutrients/growth factors to satisfy the quality requirements. 
The objective function is the sum of the costs involved in operating the 
bioreactor. Superstructure optimization impacts not only how the bioreactor is 
operated but also the way it is designed. Design choices consist of: (i) external 
diameter and length (aspect ratio) of the cylindrical bioreactor; (ii) number of 
hollow fibers for delivering reactants and extracting products and by-products. 
Operating choices include: (i) flow rate of nutritious medium through the 
bioreactor; (ii) medium inlet composition in terms of glucose and growth 
factors, (iii) ambient oxygen concentration. The optimization is constrained by 
a minimum red blood cell yield and by a sufficient amount of stem cells 
remaining in the HFBR until the end of culture. 
 
Solving the nominal bioreactor model is valuable because it indicates general 
guidelines for how to construct the bioreactor; in Misener et al. (2014b), we 
showed that the costs are competitive with rare blood transfusions (i.e., 
transfusions for patients with special needs).  However both the parameters and 
the underlying model itself are uncertain; therefore it is critical to incorporate 
uncertainty and what-if scenarios into the analysis.  Sensitivity analysis defines 
which parameters are significant; we have proposed robust optimization for 
handling the uncertainty of those parameters and used multiple runs of the same 
optimization model to explore alternative scenarios (Misener et al., 2014a; 
2014b). Recall that robust optimization inoculates against uncertainty by 
considering the worst-case realization of the parameters when optimizing the 
system (Ben-Tal and Nemirovski, 2000).  Many of the bioreactor design choices 
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remain constant despite parameter or model changes.  For example, the 
optimization model consistently favors bioreactors that are: 
 
(1) long, this results from the fixed costs per bioreactor; 
(2) thin, this reduces the dead zones from mass transfer limitations; 
(3) packed with as many hollow fibers as possible, this facilitates mass 
transfer; 
(4) operated at a high flow rate, the best mass transfer occurs with flow 
rates as high as possible which will not damage the hollow fiber 
membranes. 
 
But other of the bioreactor design choices are highly sensitive to variability. For 
example, there are two types of hollow fibers in the bioreactor; the polymeric 
hollow fibers deliver nutrients and clear waste while the ceramic hollow fibers 
deliver specialized proteins (i.e., growth factors) and harvest cells. Because the 
purpose of the bioreactor is harvesting red blood cells, the optimization 
algorithm will always try to maximize the number of ceramic hollow fibers 
subject to including enough polymeric hollow fibers for nutrient delivery. But 
uncertainties in mass transfer and cell kinetics make determining the minimum 
number of polymeric hollow fibers difficult; the tradeoff is between making 
each individual bioreactor more likely to function properly by including more 
polymeric hollow fibers or making the bioreactors which function properly 
incorporate more cell-harvesting ceramic hollow fibers.  Robust optimization 
helps quantify these tradeoffs (Appendix 1). 
4. Optimal personalized treatments for leukemia: an example of a 
type 2 system 
 
BM failure is characterized by the inability of HSCs to produce healthy blood 
cells at an acceptable rate and quality, leading to a variety of health issues and 
diseases, including leukemia. Leukemia is a cancer of the hematopoietic system 
characterized by the incapability of blood progenitors (HSCs) to mature 
normally; this induces immature white blood cells accumulation in the bone 
marrow (Williams, 1983). Acute Myeloid Leukemia (AML) is the second most 
common type of leukemia (34% of all leukemias, 2011, Cancer Research UK); 
it affects only cells from the myeloid blood lineage. According to Cancer 
Research UK, approximately 3.4 new cases of AML occur annually per 100,000 
people in the UK alone (2011).  
 
The most frequent treatment for AML is chemotherapy which aims at 
eliminating the cancerous BM population by attacking highly proliferative cells 
(immature blasts) (Cancer Research UK, American Cancer Society). 
Chemotherapy represents a reactive approach to the disease initiating after the 
disease symptoms appear. Current chemotherapy treatment protocols are designed 
based on: (i) pre-clinical animal experiments, (ii) empirical clinical trials, and (iii) 
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the acquired experience of subspecialist physicians. However, leukemia exhibits a 
very high heterogeneity both between patients and also within a specific patient 
(Preisler et al., 1995); this heterogeneity leads to unpredictable treatment outcomes. 
Clinical treatment protocols for AML could, therefore, benefit from a more rational 
and personalized treatment scheduling strategy. 
 
Increasingly, implementing more advanced pharmacokinetic/pharmacodynamic 
models becomes critical for applying personalized treatment. Additionally, 
linking a small subset of measurable variables to unique individual 
characteristics is necessary. Ultimately, applying such a tool could inform not 
only optimal timing and type of personalized treatment for improved outcomes, 
but also provide a platform for pre-clinical assessment of novel targeted 
therapies for leukemia and other cancers (Heitzig et al., 2014). Here, we review 
our efforts in simulating and optimizing chemotherapy treatment, from the time 
the drug is given to the patient, followed by the circulation in the body until it 
reaches its target (the bone marrow where leukemia resides) and finally the 
calculation of its effect according to cellular susceptibility (defined by the 
proliferative state) (Pefani et al., 2013; 2014). Detailed building blocks are 
illustrated in blue, Figure 1. 
 
4.1. In vivo: Clinical data collection from patients undergoing treatment for 
AML 
Standard treatment for AML is chemotherapy, with normally two different 
drugs: cytarabine (Ara-C) and daunorubicin (DNR). Ara-C is given twice a day 
for 10 days in a row, while DNR is given as a pulse on days 1, 3 and 5. These 
chemotherapeutic drugs act at a particular point of cell duplication. Clinical 
dosage (per body-surface area, BSA) and infusion route depend on overall 
patient fitness and age. Dosage is calculated according to the patient's weight 
and height measurements (BSA). In vivo specifications include all the details 
of the treatment (dose, schedule, infusion route etc...), patient characteristics 
(age, weight, height) and any tests performed (percentage of AML cells prior to 
chemotherapy, any follow-up measurements). 
4.2. In silico: Chemotherapy treatment optimization for AML 
Figure 4 represents an overview of the optimization model structure. For 
simulation purposes, the particular drug and schedule (chemical stimulation) 
chosen by the doctor is used as a known input for the model (Pefani et al., 
2013).  
 
Pharmacokinetics (PK) considers the transport and transformation the drug 
undergoes once it reaches the blood streams, and in turn the relevant organs 
which absorb it at different rates. Mass balances are performed in each of these 
organs, giving the drug concentration profiles. Parameters for this compartment 
include patient characteristics and treatment schedule, which can be derived 
from clinical data (always reported). 
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Chemotherapy interacts with cells that are proliferating; more specifically, only 
cells that are in one of the cell cycle phases (i.e., duplicating cells) are 
eliminated. Accordingly, detailed cell cycle equations, modeling the point of 
drug action are needed. Drug pharmacodynamics (PD) can be applied in this 
way to the susceptible cell cycle compartments of the proliferating populations. 
The drug concentration profiles calculated in the PK model are the only input 
required for the PD model, in which the drug effect on cell growth is computed 
according to cell cycle kinetics of each population. Since healthy cells also 
proliferate in order to renew the cellular material, they will equally be affected; 
it is very important to keep a balance between the number of cancer cells killed 
and the loss of healthy cells. 
 
Cell growth is modeled differently for normal and abnormal cells. Because 
most of the cancer cells are proliferating, the cell cycle model in this case 
incorporates 3 compartments in which the cells are non-resting (G0/G1, where 
cells grow and stock up on nutrients, S, where cells duplicate their DNA, and 
G2/M where cells divide; Morgan, 2007). Each of them is described by the 
mass balance between compartments (including cell death by drug action if 
applicable). The transition rates are dependent on cell cycle times and natural 
apoptosis rates in each of the phases (Basse et al., 2003); cell cycle kinetics are 
modeled through a set of Ordinary Differential Equations (ODEs) (one per 
compartment, see Appendix 2) (Pefani et al., 2014). The normal cell population 
model considers a proliferative population and a resting population that can 
move into a proliferative state, which are modeled as delay differential 
equations. A more refined multi-stage population balance model (MS-PBM) of 
the cell cycle was introduced by Fuentes-Garí et al. (2014b), based on the work 
of García Münzer et al. (2013, 2014). Duplication times of leukemic cells can 
be inferred from the number of cancer cells before and after treatment (if 
clinically performed). However, more specific information on the distribution 
within each phase is unavailable clinically and has to be determined 
experimentally (if required - see Section 4.3).   
 
Cellular metabolism is an important phenomenon in the area of cancer, as it 
influences both the tumor growth rate and its susceptibility to drugs. To 
mathematically model cellular metabolism, a mechanistic description of those 
phenomena is essential. Advanced genetic and metabolic laboratory analysis 
will enable the accurate correlation of environmental stress with the cell cycle 
via the detection, selection and quantification of intracellular biomarkers that 
have a key role on the cell stress response. Mathematical models linked to cell 
growth have been also developed by our group (Kiparissides et al., 2011) and 
will be critical in tackling personalized treatment for patients with hypo- or 
hyper- glycemia, diabetes, etc. No information on cellular metabolism is 
provided on clinical reports; any data required for parameter estimation must be 
obtained from experiments on the leukemic cells. 
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4.3. From in silico to in vitro: sensitivity analysis and design of experiments 
Insufficient in vivo data for the in silico cellular growth compartment requires 
the application of global sensitivity analysis to point out which are the 
parameters needed. GSA was performed on ODE and MS-PBM cell cycle 
models (Pefani 2014; Fuentes-Garí et al., 2014b) and identified the duration of 
each of the cell cycle phases as the most significant parameter for the cell cycle 
distribution (see Appendix 3 for a definition, Kiparissides et al. (2009) for its 
application to biological systems). Experiments were designed to accurately 
determine the sensitive parameters, based on the segregation of cells into two 
approximately synchronous populations (for the extraction of cell cycle times, 
Section 4.4.). 
 
4.4. In vitro: Laboratory data collection from AML patient cells 
Sensitivity analysis carried out in Fuentes-Garí et al. (2014b) identified cell 
cycle kinetics as one the key factors affecting treatment outcomes (Section 5.2). 
Therefore experimental efforts were directed towards (i) the determination of 
the duration of each of the cell cycle phases, (ii) the determination of the impact 
of environmental factors, such as oxygen and glucose concentration on the 
growth and cell cycle evolution, as fluctuations in the different body 
compartments and between AML patients (individual cases of hypoglycemia, 
hyperglycemia) may lead to a different leukemic cell metabolism (see as 
examples Herst et al., 2011; Lodi et al., 2011; Zhou et al., 2010). 
 
The 3D culture system of Section 3.1 provides an ideal laboratory platform to 
cukture hematopoietic cells donated by AML patients (Rende et al., 2013), 
exposing to measurement parameters crucial for cancer evolution including: 
cellular growth, cellular metabolism and drug effect. However, proof of concept 
studies linking in vitro to in silico are required as a first step to validate the 
experimental design and possibility to measure the parameters required. These 
studies are therefore carried out with leukemic cell lines (easy to handle, lab 
adapted cells), under 2D or 3D conditions. 
 
A chase experiment (Figure 5b.), which tracks labeled cells as they progress 
through the cell cycle, was designed to obtain the parameters necessary to run 
the leukemia cell growth model. Input information consisted on initial 
conditions (cell number) and experimental schedule (duration, sampling 
frequency). Parameter values for the cell cycle times of three different 
leukemia cell lines (K-562, MEC-1 and MOLT-4) were determined 
experimentally by following the timings of entry and exit events of a 
subpopulation of cells to and from each of the phases under 2D conditions at a 
first step (Fuentes-Garí et al., 2014a; 2014b). The parameters were then used to 
run the model and validate it against independent cell cycle data; good 
agreement was observed in all three cases. 
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To determine the impact of cellular metabolism on cellular growth, we 
compared in vitro the proliferation, cell cycle and metabolic evolution of an 
AML model system (K-562 cell line) in our 3D micro-bioreactor (Section 3.1) 
and in a conventional 2D culture for 2 weeks (Velliou et al., 2013; 2014a; 
2014b; 2014c). Different oxygen (5%: hypoxia; 20%: normoxia) and glucose 
conditions (4.3 g/L: standard lab; 1.3 g/L: highest in vivo; 0.6 g/L lowest in 
vivo) were used (Figure 5c.). In both the 2D and the 3D system, glucose is 
identified as the limiting factor that highly affects the kinetic evolution of K-562 
only under hypoxic conditions (Figure 6). As can be seen in Figure 7, in 
general, oxidative stress leads to a higher accumulation of cells in the resting 
phase (G0) of the cell cycle, in comparison to 20%O2, for both hypo and 
hyperglycemic levels of glucose.  
In order to assess the impact of cellular metabolism on drug effects, K-562 
was pre-cultured for one week under the aforementioned conditions and 
exposed to 10 mg/L Ara-C drug for 48h (Figure 5d., Figure 8); cells cultivated 
in hypoxia had a higher survival. This illustrates the connections between cell 
metabolism, cell growth and chemotherapy effects, and justifies the design of 
more advanced experiments that could provide enough data for parameter 
estimation in future models. 
 
5. Beyond healthy and diseased blood: treatment of diabetes and 
control of anesthesia as additional examples of type 2 systems 
5.1. Optimizing the treatment of diabetes: automated insulin dosing 
Type 1 diabetes mellitus is a disease affecting the pancreatic production of 
insulin, which regulates glucose consumption in the body. Frequent 
administration of exogenous insulin is required in order to maintain glucose 
levels in the blood within safe concentrations. Recently, efforts have been made 
to develop a more convenient and reliable alternative: the Artificial Pancreas 
(Zavitsanou et al., 2011; Dassau et al., 2013). In the Zavitsanou et al. (2011) in 
silico model of the glucoregulatory system, two chemical stimuli are delivered: 
via meals (glucose), and via insulin administration. Insulin enters directly the 
blood streams, making a transport (PK) compartment unnecessary in this case. 
After a meal, the digestion process delivers glucose to the blood streams. 
Transport to the organs is described by the glucose metabolism PK 
compartment. The PD compartment assesses the effect that insulin has on 
glucose levels in blood. The optimization problem aims at obtaining the 
optimal insulin profile that minimizes the time glucose is outside of the normal 
range.  
 
5.2. Anesthesia dosage as a control problem 
Volatile anesthesia is administered to achieve hypnosis in a patient prior to 
surgery. Clinically, anesthesia is dosed by medical specialists and requires a 
high degree of expertise. Anesthesia was previously addressed as a control 
problem in Krieger et al. (2014). The goal was to personalize drug dosage and 
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scheduling according to patient characteristics (weight, height, age, gender) and 
at a second step adjust it online according to measured response in vivo. In this 
problem, the chemical stimulus is the anesthetic agent which is delivered to the 
lungs through inhalation. It is transferred through the pulmonary capillaries to 
the blood streams, which transport the agent to other body compartments and 
tissues (muscles, skin, adipose tissue). For the in silico compartment, the PK 
model is composed by the mass balances between each of those compartments.  
Parameters required include patient characteristics and the dose administered. 
The PD model quantifies the hypnotic effect according to the PK dose, 
measured through the bispectral index. Sensitivity analysis found PD model 
parameters to be the most significant and vary widely across patients. The 
optimization and control problem on-line remains to be addressed, but on-line 
updates based on patient measurements could compensate for inaccurate PK 
parameters and deliver estimated PD parameters, increasing accuracy and 
patient-specificity of the protocols suggested. 
6. Conclusions and future perspectives  
An integrated framework was reviewed that addresses the design, modeling and 
optimization of biomedical systems.  
 
The first application presented is the optimization of healthy blood production 
artificially, comprising in vitro and in silico components. A self-contained 
bioreactor with promising RBC expansion capabilities in vitro was constructed. 
In preparation for large scale artificial blood production, optimization of the 
bioreactor superstructure in silico defined the optimal physical bioreactor layout 
and operation in order to minimize the cost of producing one unit of blood. 
 
The second application presented is the optimization of chemotherapy treatment 
strategies in leukemia, featuring in vivo, in vitro and in silico components. A 
predictive tool for the optimization of chemotherapy delivery was developed 
which a priori suggests patient-specific treatments with outcomes better than 
those resulting from current clinical protocols. Since in vivo specifications for 
each patient do not provide all the information required, the most significant 
parameters needed in silico for cellular growth are obtained in vitro. Moreover, 
cellular metabolism should be taken into consideration when designing a 
chemotherapy protocol as it significantly alters the cellular growth and drug 
action.  
 
An overview of two additional applications was given, in the areas of insulin 
dosing for diabetes and control of anesthesia. In the former, the framework was 
applied to the optimal dosage of insulin taking into account the very 
unpredictable patterns of food intake of the patient. The latter exemplifies a 
system where the control strategy can be adjusted online according to patient 
measurements. 
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Future work in the area of normal and abnormal blood expansion will focus on 
elucidating key mechanisms/factors of genetic or proteomic/metabolomics. 
Quantitative information on these key mechanisms will serve as an appropriate 
input for the construction of more detailed predictive models for the in silico 
description of healthy and diseased blood evolution. Quantification of 
appropriate intra-cellular biomarkers that are related to the blood in vitro 
kinetics can enable the combination of macroscopic kinetics with microscopic 
information both at normal and stressful environmental conditions (Velliou et 
al., 2014d). The latter will eventually lead to the construction of more detailed 
models of grey or white box nature, that will allow a much more accurate 
prediction of the cellular evolution of healthy and diseased blood. 
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Figure legends 
 
Figure 1: A framework for the design and optimization of biomedical systems 
(highlighted in orange with black arrows) and its application in the areas of 
artificial blood production (in green) and personalized leukemia treatments (in 
blue). In each example, scales are shown as rows, environments are shown as 
columns. 
 
Figure 2: (a): Geometry of the 3D micro-bioreactor (b)-(c): Scanning Electron 
microscopy (SEM) images of the highly porous 3D micro-bioreactor including 
seeded leukemic cells. 
 
Figure 3: (a) Diagram of blood-producing bioreactor (Macedo 2011); (b) Cross-
section of a bioreactor (SEM); (c)(d) Krogh Cyclinder approximation; (e) 
Poiseuille flow 
 
Figure 4: Design of clinical treatment protocols for leukemia 
 
Figure 5: Experimental design characteristics (input/output, duration, 
manpower) for (a) determination of parameters in 3D bioreactor; (b) extraction 
of cell cycle parameters for MS-PBM and for validation with phase distribution 
data; (c) characterization of metabolite effects on cellular growth in leukemia; 
(d) characterization of chemotherapeutic drug effects (Ara-C) on cellular 
growth and cell cycle evolution in leukemia. 
 
Figure 6:  K-562 growth in the 2D (a), (b) and the 3D (c), (d) system, at 
different oxygen levels: (a), (c) 20% O2 and (b), (d) 5% O2. Different colours 
represent different glucose levels: () 4.3 g/L (control), () 1.3 g/L 
(hyperglycemia), () 0.6 g/L (hyperglycemia).     
  
Figure 7: K-562 cell distribution in G0 and G1 phases of the cell cycle under 
oxidative and metabolic stress in the 2D culturing system. Different symbols 
represent different oxygen levels, i.e.,  Normoxia (20% O2) &  Hypoxia 
(5%O2). Left panels Indicate hyperglycaemia, i.e.,  (a) & (c) hyperglycaemia 
and right panels hypoglycaemia, i.e., (b) & (d). 
 
 
Figure 8: K-562 cell evolution (days 1-2) and survival (days 3-5) after 48 h 
exposure to 10 mg/L C-Ara at different oxygen levels:  control (no exposure 
to drug),  10 mg/L C-Ara  
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Appendix 
 
1. Moving towards robust optimization in the blood-producing bioreactor 
1.1. A first step is to consider which are the threshold values that are 
acceptable to operate the bioreactor experimentally.  
1.2. At a second step, the model is analyzed using sensitivity analysis, 
providing the parameters that have the most influence on model output. 
In this case, the most influential was the cellular flux across ceramic 
hollow fibers, followed by SCF half-life and cost, cellular 
differentiation and metabolism specific parameters, EPO half-life and 
price, and hollow fiber porosity. 
1.3. At a third step, the main sources of uncertainty in the model have to be 
identified. For the bioreactor, these are (1) species reaction rate; (2) 
cellular proliferation and differentiation rate; (3) exit rate of mature 
cells from the bioreactor. 
The optimization problem and a table of parameters are given below: 
 
min pk ×t k ×NR ×VolRecyc -Ck,IN + pk ×D ×Vk ×VolT
kÎ(EPO; SCF)
å
é
ë
ê
ê
ù
û
ú
ú
+ pUCB ×Hh,0 ×VolT
hÎ(Q;E;G;L)
å
é
ë
ê
ê
ù
û
ú
ú
 
s.t. 
Superstructure topology: 
NHF = NHF, PAN +NHF, CRM
eR, HF ×R4
2 ³ NHF, PAN ×R2, PAN
2 + NHF, CRM ×R2, CRM
2
VolR = p L - Le( ) R4
2 - NHF, PAN ×R2, PAN
2 - NHF, CRM ×R2, CRM
2é
ë
ù
û
VolK ,k =
p L - Le( ) ×R4
2
NHF, PAN
k = Glc, Lac
p L - Le( ) ×R4
2
NHF, PAN + NHF, CRM
k = O2
p L - Le( ) ×R4
2
NHF, CRM
k = EPO, SCF
ì
í
ï
ï
ï
ï
î
ï
ï
ï
ï
R3,k =
VolK ,k
p L - Le( )
"k
VolT = NR ×VolR
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Production requirement:
 
HQ,t +HL,t +HE,t +HG,t £ HMAX
gP,t = JCells,t × p ×NHF, CRM ×R2, CRM ×L "t Î 1,..., 5{ }
gP,tDtHE,t
t
å ³ UnitRBC
 
 
Species transfer: 
Ck,MIN £Ck,i(r,z) £Ck,MAX "i,k
Ck,OUT = R2 -
R1
2
R2
æ
è
ç
ö
ø
÷×
NHF ×Vk
UZ
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è
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11
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2 ×eHF
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Proliferation & differentiation: 
HQ,t -HQ,t-1
Dt
= -(kE,t-1 +kG,t-1 +kL,t-1) ×HQ,t-1 + (2 ×e
-gS ×tQ -1) ×b
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Symbol Description
 
Units
 
A
b
b
re
v
ia
ti
o
n
s 
BM Bone marrow  
HF Hollow fiber  
HFMB Hollow fiber membrane bioreactor  
HSC Haematopoietic stem cell  
PAN Polyacrilonitrile  
PU Polyurethane  
RBC Erythrocyte, red blood cell  
UCB Umbilical cord blood  
In
d
ic
es
 
h 
Haematopoietic cells; ℎ ∈ {𝑄, 𝐸, 𝐿, 𝐺} where           𝑄 ≡ HSC, 𝐸 ≡ RBC,  
𝐿 ≡ lymphocytes, 𝐺 ≡ granulocytes  
i 
Bioreactor region; 𝑖 ∈ {1, … , 𝐼} where             1 ≡ hollow fiber lumen, 
 2 ≡ hollow fiber membrane, 
 
3 ≡ polyurethane scaffold; one Krogh cylinder, 
4≡entire bioreactor 
 
k 
Species; 𝑘 ∈ {Glc, Lac, O2, EPO, SCF} where Glc ≡ glucose, Lac ≡ lactate,  
O2 ≡ oxygen, EPO ≡ erythropoietin, SCF ≡ stem cell factor  
t Time period in weeks; 𝑡 ∈ {1, … ,5}  
P
ar
am
et
er
s 
Ck, MIN Allowable concentration range of species k  
Ck, MAX CGlc, CLac, C𝑂2[=] 
mol
m3
, CEPO[=] 
U
m3
, CSCF[=] 
mg
m3
  
D Days at steady state culture conditions 35 days 
𝜖𝑅,𝐻𝐹 Maximum HF packing density in reactor 0.14 
HMAX Maximum cell density 
0.5× 10-6 
cells/mm3 
Ri 
Radius of region 𝑖 ∈ {1,2}               RCRM, 1 = 0.25 mm; RCRM, 2 = 0.43 mm  
RPAN, 1 = 0.26 mm; RPAN, 2 = 0.45 mm 
UnitRBC Number of RBC in one unit 
2× 1012 
cells 
VolRecyc Recycle volume needed for each reactor 
1.0× 10-4 
m3 
U
n
ce
rt
ai
n
 P
ar
am
et
er
s 
Ah 
Amplification parameter for differentiation ℎ ∈ {𝐸, 𝐿, 𝐺} 
 
AE = 5.63 × 10
5; AG = 2.82 × 10
5;  AL = 7.52 × 10
4 
Dk, i Diffusivity of species k in region 𝑖 ∈ {1,2,3} m
2/s 
𝜖PU;  𝜖HF Porosity of HF and PU scaffold                      𝜖PU = 0.79 ±  0.1; 𝜖PU = 0.8   
𝛾ℎ 
Death rate (non-age) of differentiated cells; ℎ ∈ {𝐸, 𝐿, 𝐺}  
𝛾E =  0.001 days
−1;  𝛾G =  0.15 days
−1;  𝛾L =  2.4 days
−1  
𝛾𝑄 Death rate of HSC during proliferation 0.1 days
−1 
𝐽Cells 
Cellular flux across ceramic HF when ∆?̂?Cells = 1.0 × 10
6 cells/mm3  
𝐽Cells  =  5.76 ±  2.25 × 10
5 cells/mm2/day  
p𝑘 Price of species k                  pEPO =  0.023 US $ /U; pSCF =  320 US $ /mg  
pUCB Price of umbilical cord blood 
US $ 220 
/ 4× 108 
nucleated 
cells 
t1/2, 𝑘 Growth factor half-life                          t1/2, EPO = 3 days; t1/2, SCF = 2 days  
τQ Stem cell proliferation time 1.4 days 
𝑉𝑘 
Maximum reaction rate of species k  in the scaffold  
VGlc, VLac, V𝑂2[=] 
mol
m3 day
, VEPO[=] 
U
m3 day
, VSCF[=] 
mg
m3 day
  
𝑉𝑂2,𝑘 
Reaction rate of O2 with cell type h in the scaffold  
V𝑂2, HSC = 3.89 × 10
−14 
 mol
cell day
 ;  V𝑂2, RBC = 1.56 × 10
−13
 mol
cell day
 
 
V𝑂2, Gran = 1.56 × 10
−11
 mol
cell day
;  V𝑂2, Gran = 1.2 × 10
−12
 mol
cell day
 
 
 
A systematic framework for the design, simulation and optimization of of personalized healthcare: 
making and healing blood 31 
D
ec
is
io
n
 V
ar
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b
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s 
𝐶𝑘, IN 
Conc. of species k at bioreactor inlet  
                                CGlc, IN, CLac, IN, C𝑂2, IN[=]
mol
m3
,CEPO, IN[=]
U
m3
, CSCF, IN[=]
mg
m3
  
L Length of bioreactor                          ?̂? = 150 mm;  𝐿 ∈ [50 mm, 200 mm]  
NHF Number of hollow fibers                                     N̂HF = 8; NHF  ∈ {1, . . . ,20}  
NHF, CRM Number of ceramic HF                          N̂HF, CRM = 4; NHF, CRM  ∈ {1, . . . ,20}  
NHF, PAN Number of polymeric HF                       N̂HF, PAN = 4; NHF, PAN  ∈ {1, . . . ,20}  
NR  Number of equivalent bioreactors                                                      N̂𝑅 = 1  
R4 Radius of region  𝑖 =  4 mm                           R̂4 = 3.75 mm; R4  ∈ [2, 10]  
UZ 
Bulk liquid velocity in the HF   𝑈𝑍 = 7.1 × 10
−2 mm/s; 𝑈𝑍  ∈
[𝑈𝑍, 2 ∙ 𝑈𝑍] 
 
D
ep
en
d
en
t 
V
ar
ia
b
le
s 
𝛽𝑄,𝑡 Rate of entry into the proliferative phase days
-1 
𝐶𝑘,𝑖(r, z) 
Conc. of species k in region i at location (r, z)  
CGlc, i(r, z), CLac, i(r, z), C𝑂2,𝑖(r, z)[=]
mol
m3
,CEPO, i(r, z)[=]
U
m3
, CSCF, i(r, z)[=]
mg
m3
   
𝐶𝑘, OUT 
Conc. of species k at bioreactor outlet  
                    CGlc, OUT, CLac, OUT, C𝑂2, OUT[=]
mol
m3
,CEPO, OUT[=]
U
m3
, CSCF, OUT[=]
mg
m3
   
𝛾𝑃,𝑡 Production rate of cells from the bioreactor days
-1 
𝐻ℎ,𝑡 Cell types ℎ ∈ {𝑄, 𝐸, 𝐿, 𝐺} in region 3 for 𝑡 ∈ {1, … ,5} cells / m
3 
𝐽Cells Cellular flux across ceramic HF  
𝜅ℎ,𝑡 Differentiation rate towards committed lineages ℎ ∈ {𝐸, 𝐿, 𝐺} days
-1 
R3 Radius of region 𝑖 ∈ {3} mm 
r Radial distance from center of Krogh cyclinder mm 
Rxn𝑘  
Reaction rate of species 𝑘; 0th -order approx  
RxnGlc, RxnLac, Rxn𝑂2[=] 
mol
m3 day
, RxnEPO[=] 
U
m3 day
, RxnSCF[=] 
mg
m3 day
   
τ𝑘 Rate for replenishing growth factor - 
Vol𝐾,𝑘 Krogh volume for each species 𝑘 ∈ {Glc, Lac, O2, EPO, SCF} m
3 
Vol𝑅 Reactor volume m
3 
Vol𝑇 Total volume m
3 
z Axial distance along the bioreactor mm 
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2. Model equations 
2.1. Pharmacokinetics (Pefani et al., 2013) 
Drug transport 
in blood  
 
VB ×
dCB, j
dt
= Qi ×Ci, j +QK ×CK , j -QB ×CB, j
i:H ,Li,M ,Le
j:ara-C,DNR
å + In j
 
where: 
VB : volume of blood 
CB,j : concentration of drug j in the blood 
Qi : blood flow in organ i 
QK : blood flow in kidneys 
QB : blood flow in blood 
CK,j : concentration of drug j in kidneys 
Ci,j : concentration of drug j in organ i 
Inj : inflow rate of infusion (mg/h) 
Drug excretion 
by other organs 
(i) 
Vi ×
dCi, j
dt
=Qi ×CB, j -Qi ×Ci, j - kK , j ×CB, j ×Vi,T
  
where: 
Vj : volume of organ i 
Ci,j : concentration of drug j in organ i 
Qi : blood flow in organ i 
CB,j : concentration of drug j in blood compartment 
kK,j : drug clearance rate by the kidneys 
Vj,T : volume of organ tissue
 
Cumulative drug 
excretion U j = kK , j ×CB, j, j dt
0
t
ò
 
where: 
Uj : cumulative drug excretion 
kK,j : drug clearance rate by the kidneys 
CB,j : concentration of drug j in blood compartment 
Inflow drug dose 
In j =
dose j
duration j  
where: 
Inj : inflow rate of infusion (mg/h) 
dosej : clinical dose administered to patient (mg) 
durationj : duration of the infusion of drug j 
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Clinical practice 
drug dose 
calculation 
dosej = uj ×bsa
 where 
bsa =
height ×weight
3600  
where: 
dosej : clinical dose administered to patient (mg) 
uj : drug dose in mg/m2 (drug j) 
bsa : body surface area 
height, weight: actual height and weight of the patient 
 
2.2. Pharmacodynamics (Pefani et al., 2013) 
Drug effect on 
cell cycle phase effecty, j =
Emax,y, j ×CM ,y, j
slope
E50,y, j +CM ,y, j
slope
 
where: 
Emax,y,j : maximum drug effect 
E50,y,j : concentration at half-drug effect (drug j) 
CM,y,j : concentration of drug j at the location of the tumor 
slope: scaling factor for DNR drug action 
effecty,j (CM,y,j) : effect of drug j on phase y (dependant on PK 
calculations for CM,y,j) 
 
2.3. Cell cycle 
 
N
o
rm
a
l 
ce
ll
 
cy
cl
e
 
(P
ef
a
n
i 
et
 
a
l.
, 
2
0
1
3
) 
 
Quiescent population: 
dQ
dt
= -d ×Q(t)-b(Q(t)) ×Q(t)+2 ×e-g (t ) × b(Q(t)) ×Q(t)- effectQ, j ×Q(t) 
Proliferating population: 
dP
dt
= -g ×P(t)+b(Q(t)) ×Q(t)- e-g (t ) × b(Q(t)) ×Q(t)-effectP, j ×P(t)
 
with: 
b(Q(t))= b0 ×q
n / (q n +Q(t)n ) 
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O
D
E
s 
(P
ef
a
n
i 
et
 
a
l.
, 
2
0
1
3
) 
dPy
dt
= ry-1(Ty-1) ×Py-1 - ry(Ty ) ×Py - effecty, j ×Py
 
where: 
Py(t) : population function ( y = G0/G1 (1), S (2) or G2/M (3) compartment) 
Ty : duration of cell cycle phase y 
ry(Ty) : transition function (from y phase to y+1 phase, where y+1 = 1 if y =3) 
effecty,j : effect of drug j on phase y (dependant on PK calculations) 
 
 
P
B
M
 (
F
u
en
te
s-
G
a
rí
 e
t 
a
l,
 2
0
1
4
) 
¶Py
¶t
+
¶Py
¶sy
=a × ry-1(sy-1, t) ×Py-1 dsy-1
s
y-1, min
s
y-1, max
ò - ry(sy, t) ×Py - effect j ×Py
 
where: 
sy : state variable for phase y ( y = G0/G1 (1), S (2) or G2/M (3) compartment) 
Py(sy,t) : population function for phase y 
Ty : duration of cell cycle phase y 
ry(sy,t) : transition function (from y phase to y+1 phase, where y+1 = 1 if y =3) 
effecty,j : effect of drug j on phase y (dependant on PK calculations) 
α : boundary condition constant: α=1 if sy=sy,min and α=0 elsewhere 
 
in the discretized form: 
 
iyjyiyiyyiyyiyy
N
j
jyjy
iy
PeffectPtsrPkPktsr
dt
dP j
,,,,,1,
1
,1,1
,
),(),(  


 
i: discretization index for phase y 
j: discretization index for phase y-1 (phase y-1 = 3 if y = 1)  
Nj : number of discretization intervals in phase y-1 
sy,i : state variable for phase y ( y = G0/G1 (1), S (2) or G2/M (3) compartment) 
at discretization index i 
Py,i(t) : population function for phase y at discretization index i 
Ty : duration of cell cycle phase y 
ry,i(sy,i,t) : transition function (from y phase to y+1 phase, where y+1 = 1 if y =3) 
at discretization index i 
effecty,j : effect of drug j on phase y (dependant on PK calculations) 
α : boundary condition constant: α=1 if i=1 and α=0 elsewhere 
 
 
 
3. Global sensitivity analysis 
GSA is a powerful technique in the analysis of model robustness with respect to 
each of its parameters. Briefly, performing GSA involves varying all of the 
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estimated/experimentally determined parameters simultaneously using Sobol's 
method, and observing the model's output. When the output is highly altered in 
correlation with varied specific parameters, these are said to be significant and 
an accurate determination of each of them is needed. Conversely, if the output 
remains unchanged, the parameters are not significant and they can be estimated 
or left at their nominal values without significant impact on the model's 
predictions. A concise overview of the GSA method is given below. 
The Sobol’s sensitivity analysis method is a variance based approach based 
on the anova decomposition
1,2
. If 𝑓 is an integrable function defined on the unit 
hypercube 𝐼𝑛and 𝑥𝜖𝐼𝑛, 𝑥 = (𝑥1, … , 𝑥𝑛) the input variables, the output 𝑓(𝑥) of 
the function may be expressed as: 
𝑓(𝑥) = 𝑓0 + ∑ ∑ 𝑓𝑖1…𝑖𝑠(𝑥𝑖1 , …
𝑛
𝑖1<⋯<𝑖𝑠
𝑛
𝑠=1
, 𝑥𝑖𝑠) 
 
  
𝑓0is the mean response of 𝑓and the terms 𝑓𝑖(𝑥𝑖)and 𝑓𝑖𝑗(𝑥𝑖,𝑥𝑗) represent the first 
and second order terms and so on. The formula above is termed ANOVA 
decomposition. The component functions may then be expressed as integrals of 
𝑓: 
∫ 𝑓(𝑥)𝑑𝑥 = 𝑓0 
∫ 𝑓(𝑥) ∏ 𝑑𝑥𝑘 = 𝑓0 + 𝑓𝑖(𝑥𝑖
𝑘≠𝑖
) 
∫ 𝑓(𝑥) ∏ 𝑑𝑥𝑘 = 𝑓0 + 𝑓𝑖(𝑥𝑖
𝑘≠𝑖,𝑗
) + 𝑓𝑖𝑗(𝑥𝑖 , 𝑥𝑗) 
 
 
 
If it is assumed that𝑓 is square integrable over 𝐼𝑛, we have: 
 
∫ 𝑓2(𝑥)𝑑𝑥 − 𝑓0 = ∑ ∑ ∫ 𝑓𝑖1…𝑖𝑠𝑑𝑥1 … 𝑑𝑥𝑠
𝑛
𝑖1<⋯<𝑖𝑠
𝑛
𝑠=1
 
 
 
 
𝐷 = ∫ 𝑓2(𝑥)𝑑𝑥 − 𝑓0and𝐷𝑖1…𝑖𝑠 = ∫ 𝑓𝑖1…𝑖𝑠𝑑𝑥1 … 𝑑𝑥𝑠 
 
 
 
The terms represent the variance and partial variance respectively. The Sobol’s 
sensitivity indices (SI) are given by: 
                                                 
1 Sobol IM (2001) Global sensitivity indices for nonlinear mathematical models and their Monte 
Carlo estimates. Mathematics and Computers in Simulation 55(1-3):271-280. 
2 Sobol IM & Kucherenko SS (2005) On Global sensitivity analysis of quasi-Monte Carlo 
algorithms. Monte Carlo Methods and Applications 11(1):83-92. 
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𝑆𝑖1…𝑖𝑠 =
𝐷𝑖1…𝑖𝑠
𝐷
 
 
 
 
where: 
∑ ∑ 𝑆𝑖1…𝑖𝑠 = 1
𝑛
𝑖1<⋯<𝑖𝑠
𝑛
𝑠=1
 
 
 
If a set of variables 𝑦 = (𝑥1, … , 𝑥𝑠)is considered and 𝑧 a set of the 
complementary variables, we note 𝑥 = (𝑦, 𝑧). Using the previous definition of 
the variance the total variance of the subset 𝑦 can be computed as: 
 
𝐷𝑦
𝑡𝑜𝑡 = 𝐷 − 𝐷𝑧  
 
and: 
𝑆𝑦
𝑡𝑜𝑡 =
𝐷𝑦
𝑡𝑜𝑡
𝐷
  
 
The following inequality holds:  
0 ≤ 𝑆𝑦 ≤ 𝑆𝑦
𝑡𝑜𝑡 ≤ 1  
If 𝑆𝑦 = 𝑆𝑦
𝑡𝑜𝑡 = 0 then 𝑓 does not depend on 𝑦. 
If 𝑆𝑦 = 𝑆𝑦
𝑡𝑜𝑡 = 1 then 𝑓only depends on 𝑦. 
 
The indices enable us to rank variables and discard unessential variables. 
Sensitivity analysis indices are usually computed through monte-carlo 
numerical integration
3
. 
𝐷𝑦 = ∫ 𝑓(𝑥)𝑓(𝑦, 𝑧)𝑑𝑥𝑑𝑧 − 𝑓0
2  
 
                                                 
3 Sobol IM (2001) Global sensitivity indices for nonlinear mathematical models and their Monte 
Carlo estimates. Mathematics and Computers in Simulation 55(1-3):271-280. 
38  M. Fuentes-Garí et al. 
 
